» Articles » PMID: 22889110

Headache in Essential Thrombocythaemia

Overview
Publisher Wiley
Specialty General Medicine
Date 2012 Aug 15
PMID 22889110
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Headache is frequently reported as one of the neurological manifestations of essential thrombocythaemia (ET) and other myeloproliferative neoplasms. It is associated with considerable morbidity; yet, it is a frequently under-recognised symptom. In patients with ET, headaches may be attributable to the disease, to the prescribed ET treatment, or unrelated to ET. The majority of headaches in ET are self-limiting and can be managed with standard headache therapies such as paracetamol, but it is vital that the clinician managing these conditions is able to recognise the headaches with a more sinister pathology. In this article, we will review the incidence and management of headaches in ET, whether they are primarily related to the disease or a result of its treatment. Identification of specific headache types in patients with ET may enable physicians to employ the most effective headache medication. This would enhance the patient-physician relationship, increasing patient compliance and thus reducing the risk of adverse outcomes.

Citing Articles

Clinical characteristics and management of headache in patients with myeloproliferative neoplasms.

Shimoyama T, Yamaguchi H, Kimura K, Suzuki F, Hayashi T, Wakita S Front Neurol. 2022; 13:1051093.

PMID: 36561301 PMC: 9764390. DOI: 10.3389/fneur.2022.1051093.


A phase 3b, multicenter, open-label extension study of the long-term safety of anagrelide in Japanese adults with essential thrombocythemia.

Kanakura Y, Shirasugi Y, Yamaguchi H, Koike M, Chou T, Okamoto S Int J Hematol. 2018; 108(5):491-498.

PMID: 30121892 DOI: 10.1007/s12185-018-2510-7.


Clinical Characteristics of Cerebrovascular Pathology with Patients Suffering from Ph-Negative Myeloproliferative Disease.

Tanashyan M, Kuznetsova P, Shabalina A, Raskurazhev A, Lagoda O, Subortseva I Cerebrovasc Dis Extra. 2016; 6(3):66-70.

PMID: 27598581 PMC: 5040904. DOI: 10.1159/000448597.

References
1.
Seiler S, ARNOLD A, Grove R, Fifer C, Keely Jr S, STANTON H . Effects of anagrelide on platelet cAMP levels, cAMP-dependent protein kinase and thrombin-induced Ca++ fluxes. J Pharmacol Exp Ther. 1987; 243(2):767-74. View

2.
Jabaily J, Iland H, Laszlo J, Massey E, Faguet G, Briere J . Neurologic manifestations of essential thrombocythemia. Ann Intern Med. 1983; 99(4):513-8. DOI: 10.7326/0003-4819-99-4-513. View

3.
Aamodt A, Borch-Iohnsen B, Hagen K, Stovner L, Asberg A, Zwart J . Headache prevalence related to haemoglobin and ferritin. The HUNT Study. Cephalalgia. 2004; 24(9):758-62. DOI: 10.1111/j.1468-2982.2004.00756.x. View

4.
Ho C . White blood cell and platelet counts could affect whole blood viscosity. J Chin Med Assoc. 2004; 67(8):394-7. View

5.
Ickenstein G, Klotz J, Langohr H . [Headache caused by polycythemia vera. Classification of a headache under the heading of metabolic disturbances]. Schmerz. 2003; 13(4):279-82. DOI: 10.1007/s004829900006. View